Synthesis method of cefditoren pivoxil
By simplifying the synthesis process of ceftolonpiester and using the reaction of 7-ATCA with AE active esters and sodium bicarbonate, the problems of complex and low purity of the existing process are solved, and efficient ceftolonpiester production is achieved, improving the Product quality and industrial applicability.
Patent Information
- Application Number
- CN202411034016.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-30
- Publication Date
- 2024-11-15
AI Technical Summary
The existing cefotorolinpiester synthesis process is complex, with high reaction temperature and high impurity and isomer content, resulting in poor purity and low product conversion rate, affecting industrial production.
Using 7-ATCA as the starting material, condensation reaction with AE active ester and catalyst triethylamine, followed by salt with sodium bicarbonate, and finally esterified with methyl pivalate. By controlling temperature and solvent selection, it simplifies Process route to improve purity and yield.
The content of Δ-3 isomers and total impurities is reduced, the purity and molar yield of ceftorolinpiester are improved, the process route is simplified, the industrial production costs are reduced, and the product quality stability is improved.
Smart Images

Figure CN118955531A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of antibiotic synthesis, and particularly relates to a method for synthesizing cefditoren pivoxil. Background Art
[0002] Cefditoren pivoxil, its chemical name: (-)-(6R,7R)-2,2-dimethylpropionyloxymethyl 7-[(Z)-2-(2-amino-4-thiazolyl)-2-methoxyiminoacetylamino]-3-[(Z)-2-(4-methyl-5-thiazolyl)vinyl]-8-oxo-5-thia-1-azabicyclo[4,2,0]oct-2-ene-2-carboxylate, molecular formula: C 25 H 28 N6O7S3, molecular weight: 620.73, CAS number: 117467-28-4, molecular structure is shown in the figure below:
[0003]
[0004] Cefditoren pivoxil was developed by Meiji Seika Co., Ltd. of Japan. It is a third-generation oral cephalosporin antibiotic and was launched in Japan in 1994. Cefditoren pivoxil has a wide spectrum and high-efficiency antibacterial characteristics, especially for respiratory tract infections with strong bacterial resistance. Compared with similar antibiotics currently used in clinical practice, it has a stronger antibacterial effect on resistant strains. The post-marketing clinical evaluation efficacy is: 93.1% in the field of dermatology, 100% in the field of surgery, 97.9% in the field of respiratory medicine, 94.6% in urinary tract infection, 100% in scarlet fever, 100% in pertussis, and 100% in otolaryngology; this product is particularly suitable for pneumococcal infection, and among common community-acquired pathogens, it has reduced resistance to penicillin or β-lactamase-mediated drugs.
[0005] It is a recommended drug for children. Its antibacterial spectrum covers the common pathogens of children's respiratory system and ENT infections in a balanced manner. It is recommended by the Japanese Guidelines for the Management of Respiratory Infectious Diseases in Children (2007); the Clinical Practice Guidelines for the Diagnosis and Management of Acute Otitis Media in Children (2006) recommends this drug granules as an oral cephalosporin antibiotic for the treatment of this disease; low-dose and high-dose regimens of this drug have similar clinical outcomes in the treatment of uncomplicated rhinosinusitis in children. In short, its safety or efficacy in pediatric patients with acute otitis media did not cause any concerns, which once again confirmed its efficacy and safety.
[0006] At present, there is relatively little research on the synthesis process technology of cefditoren pivoxil, and the existing synthesis technology process is relatively complicated. It mainly uses 7-ATCA as the starting material, and obtains cefditoren pivoxil through a series of reactions such as addition reaction, Wittig reaction, deprotection, sodium salt formation and esterification. The purity of the product obtained by this traditional process route is unstable, and the reaction process and treatment process are quite complicated, which is not conducive to industrial production. For example: in the synthesis of cefditoren sodium, tetrahydrofuran and water are used as reaction solvents in the traditional technical scheme, and the reaction is carried out at 15-20°C. After the reaction is completed, ethyl acetate and water are used for extraction. After separation, the pH is adjusted to obtain cefditoren acid solid, and then the cefditoren acid solid is dissolved in acetone / water, and sodium isooctanoate solid is added to react to obtain cefditoren sodium; then the esterification reaction is carried out with iodine methyl pivalate, and then ethyl acetate, isopropanol and other solvents are added for extraction for many times. The whole process is complicated to operate, with many steps, many types of solvents and large quantities; the process of precipitating cefditoren acid solid is complicated and the impurity removal effect is not obvious; sodium isooctanoate is used in the salt formation with cefditoren acid, resulting in poor purity of cefditoren sodium, low product conversion rate, high industrial production cost, and is not conducive to market promotion and application.
[0007] The information disclosed in this background technology section is only intended to enhance the understanding of the overall background of the invention and should not be regarded as an acknowledgment or any form of suggestion that the information constitutes the prior art already known to a person skilled in the art. Summary of the invention
[0008] The technical problem to be solved by the present invention is that the reaction process and treatment process of the existing synthesis technology are complicated, the reaction temperature is high, and the impurity and isomer content are high, resulting in poor purity of cefditoren sodium and low product conversion rate.
[0009] In order to solve the above technical problems, the present invention provides a method for synthesizing cefditoren pivoxil, which comprises the following steps:
[0010] (1) Using the cephalexin intermediate 7-ATCA (7-amino-3-[(Z)-2-(4-methyl-5-thiazolyl) vinyl]-3-cephem-4-carboxylic acid) as the starting material, a condensation reaction is carried out with AE active ester (2-methoxyimino-2-(2-amino-4-thiazolyl)-(z)-benzothiazolyl thioacetate) under the action of a catalyst triethylamine to obtain cefditoren acid shown in Formula I, and the reaction formula is as follows:
[0011]
[0012] (2) The cefditoren acid shown in formula I is subjected to a salt-forming reaction with sodium bicarbonate to obtain the cefditoren sodium shown in formula II, and the reaction formula is as follows:
[0013]
[0014] (3) The cefditoren sodium shown in formula II is subjected to an esterification reaction with iodomethyl pivalate, and then subjected to extraction, washing, distillation concentration, and drying steps to obtain the product cefditoren pivoxil shown in formula III. The reaction formula is as follows:
[0015]
[0016] In one or more embodiments of the present invention, the specific steps of step (1) include: adding the cephalosporin intermediate 7-ATCA and AE active ester to tetrahydrofuran, adding catalyst triethylamine, and controlling the solution temperature to be within 0-5°C, stirring the reaction after the addition is completed until the solution becomes clear, and obtaining the cefditoren acid shown in formula I; the molar ratio of the 7-ATCA, AE active ester and triethylamine is 1:(1.0-1.5):(1.0-1.5); preferably, the molar ratio of the 7-ATCA, AE active ester and triethylamine is 1:(1.0-1.3):(1.0-1.3); most preferably, the molar ratio of the 7-ATCA, AE active ester and triethylamine is 1:1.1:1.2.
[0017] In one or more embodiments of the present invention, the reaction time in the above step (1) is 2-5 hours; preferably, the reaction time is 3 hours.
[0018] In one or more embodiments of the present invention, the obtained cefditoren acid represented by formula I is sampled and the 7-ATCA residue is detected by HPLC. The reaction is terminated when the residue is less than ≤1.0%.
[0019] In one or more embodiments of the present invention, the specific steps of step (2) include: extracting the cefditoren acid solution of formula I obtained in step (1) with an organic solvent, reacting it with sodium bicarbonate, and fully stirring for crystallization; then filtering with suction, washing the material with acetone, and vacuum drying to obtain cefditoren sodium of formula II; wherein the molar ratio of 7-ATCA to sodium bicarbonate is 1:(0.52-0.65); preferably, the molar ratio of 7-ATCA to sodium bicarbonate is 1:(0.54-0.59); most preferably, the molar ratio of 7-ATCA to sodium bicarbonate is 0.54:0.56.
[0020] The weak base crystallization technology mentioned above solves the problem that it is difficult to control the pH value in the crystallization process, which causes decomposition and damage to the product, forms impurities, and affects product quality.
[0021] Traditional cefditoren pivoxil uses sodium hydroxide or sodium isooctanoate as a salt-forming agent in the sodium salt synthesis process, which has major quality defects, mainly manifested as: sodium hydroxide has a strong alkalinity, which easily causes a local over-alkalinity pH value during the salt crystallization process, causing the product to decompose rapidly under strong alkaline conditions and produce impurities, ultimately affecting the product quality; although sodium isooctanoate is a weak base salt-forming agent, it will introduce a new impurity, isooctanoic acid, during the salt-forming process, and it is difficult to completely remove it in post-treatment, which also affects the quality of the final product. This technology uses sodium bicarbonate as a salt-forming agent, which reacts weakly during the salt-forming process and produces by-products of water and carbon dioxide. It better solves the problem of salt decomposition or introduction of impurities and improves the quality of the final product.
[0022] In one or more embodiments of the present invention, the organic solvent in the above step (2) is dichloromethane; the washing method in the above step (2) is two washes; the time for each wash is 10-30 minutes, preferably, the time for each wash is 15 minutes.
[0023] The present invention adopts dichloromethane washing in step (2) to dissolve the unreacted excess AE-active ester in the dichloromethane organic phase for washing and two-phase separation to remove impurities. In the catalytic reaction process, excessive side chain AE-active ester is used. The present invention adopts two dichloromethane washings in the above step (2) to remove the excessive side chain AE-active ester, thereby improving the purity of cefditoren sodium.
[0024] In one or more embodiments of the present invention, the crystallization time in the above step (2) is 1-4 hours; preferably, the crystallization time is 1 hour, 2 hours, 3 hours, or 4 hours.
[0025] In one or more embodiments of the present invention, the vacuum drying temperature in the above step (2) is 30-50°C; preferably, the vacuum drying temperature is 40°C.
[0026] In one or more embodiments of the present invention, the specific steps of step (3) include: adding the cefditoren sodium shown in formula II obtained in step (2) to dimethylformamide, heating to dissolve and then cooling; then slowly adding iodomethyl pivalate to react, and controlling the solution temperature to be within -10°C to -15°C; then subjecting the mixture to organic solvent extraction, water washing, reduced pressure distillation, crystallization, cooling, suction filtration, washing, and vacuum drying to obtain the product cefditoren pivoxil shown in formula III; wherein the molar ratio of cefditoren sodium to iodomethyl pivalate is 1:(1.0-1.5); preferably, the molar ratio of cefditoren sodium to iodomethyl pivalate is 1:(1.0-1.3); most preferably, the molar ratio of cefditoren sodium to iodomethyl pivalate is 1:1.1.
[0027] In one or more embodiments of the present invention, the temperature of the heating in the above step (3) is 25°C-45°C; preferably, the heating temperature is 35°C.
[0028] In one or more embodiments of the present invention, the cooling temperature is -15°C.
[0029] In one or more embodiments of the present invention, the reaction time is 3-4 hours.
[0030] In one or more embodiments of the present invention, the organic solvent in the above step (3) is ethyl acetate; the extraction method in the above step (3) is two extractions, both of which are ethyl acetate extractions; after the two extractions are completed, water washing is performed again; preferably, the water washing is purified water washing.
[0031] The present invention transfers the main product cefditoren pivoxil to the organic phase through two extractions with ethyl acetate, thereby improving the product yield; the purified water washing mainly involves washing the organic phase obtained by extraction with water once, and transferring the water-soluble impurities in the ethyl acetate organic phase to the aqueous phase, thereby playing a role in purification and impurity removal. In one or more embodiments of the present invention, the first extraction time in the above step (3) is 25-40 minutes, and the second extraction and water washing time is 10-30 minutes; preferably, the first extraction time is 30 minutes, and the second extraction and water washing time is 15 minutes.
[0032] After the esterification reaction is completed, the concentration of the main product cefditoren pivoxil is high. Through long-term stirring extraction, the material can be fully transferred to the organic phase, thereby improving the product yield. Because the water-soluble impurities in the organic phase are small and easy to wash and remove, an additional washing is performed.
[0033] In one or more embodiments of the present invention, the crystallization in the above step (3) is ethanol crystallization.
[0034] In one or more embodiments of the present invention, the washing in the above step (3) is ethanol immersion washing.
[0035] In one or more embodiments of the present invention, the product cefditoren pivoxil of formula III is sampled and the reaction is monitored by HPLC. When the residual cefditoren sodium is less than ≤1.0%, the reaction is stopped.
[0036] In one or more embodiments of the present invention, the temperature of vacuum drying in the above step (3) is 40°C.
[0037] Compared with the prior art, the present invention has at least the following beneficial effects:
[0038] (1) The present invention uses sodium bicarbonate as a salt-forming agent, and a weak base reaction is performed during the salt-forming process, and water and carbon dioxide are produced as byproducts, thereby solving the problem that the difficulty in controlling the pH value during the crystallization process causes decomposition and damage to the product, forms impurities, and affects the product quality. The problem of salt decomposition or introduction of impurities is solved. Compared with the process of preparing cefditoren pivoxil by reacting cefditoren acid with sodium isooctanoate or cefditoren acid with diisopropylamine, the present invention can effectively reduce the Δ-3 isomer content, the maximum single impurity and the total impurity. At the same time, it can effectively increase the cefditoren pivoxil content and the molar yield of cefditoren pivoxil, thereby improving the overall quality of the final product.
[0039] (2) The synthetic process of the present invention is short, the reaction control conditions are mild, and it is easy to industrialize; the reaction solvent system is simple, the organic solvent components used are simple and easy to recycle, the product conversion rate is high, and the product quality is stable. BRIEF DESCRIPTION OF THE DRAWINGS
[0040] Figure 1 is a process roadmap for preparing cefditoren sodium according to one embodiment of the present invention;
[0041] Figure 2 The present invention is a process roadmap for preparing cefditoren pivoxil according to one embodiment of the present invention. DETAILED DESCRIPTION
[0042] The present invention is described in detail below in conjunction with test examples and specific implementation methods, but it should be understood that the protection scope of the present invention is not limited by the specific implementation methods.
[0043] Unless otherwise explicitly stated, throughout the specification and claims, the term "comprise" or its variations such as "include" or "comprising" will be understood to include the stated elements or components but not to exclude other elements or components. Figure 1 and Figure 2 , the following embodiments are described in detail.
[0044] Example 1: A method for synthesizing cefditoren pivoxil
[0045] Add 30 mL of tetrahydrofuran and 140 mL of purified water to the reaction flask, stir and cool to 0-5°C; add 50 g (154.6 mmol) of 7-ATCA and 59.6 g (170.06 mmol) of AE active ester to the reaction flask, wash the flask wall with 15 mL of purified water, continue stirring and cool to 0°C; slowly drop 18.8 g (185.5 mmol) of triethylamine to the reaction solution, and control the solution temperature within 0-5°C. After the dropwise addition is completed, stir and react for 3 hours until the solution becomes clear; take a sample and detect the 7-ATCA residue by HPLC. The reaction is terminated if it is less than ≤1.0%.
[0046] Add 500mL of dichloromethane to the reaction flask, stir and wash for 15 minutes; separate the layers, retain the aqueous phase, add 300mL of dichloromethane, stir and wash for 15 minutes; separate the layers, retain the aqueous phase, and transfer it to another reaction flask, add 500mL of acetone; stir and warm to 25°C; add 7.14g (85.0mmol) of sodium bicarbonate to the reaction flask in portions, stir and crystallize for 2 hours; filter with suction, wash the material with 170mL of acetone, and vacuum dry at 40°C to obtain 46.0g (82.8mmol) of cefditoren sodium.
[0047] Add 250mL dimethylformamide and 35g (63mmol) of cefditoren sodium to the reaction flask, heat to 35°C, and stir to dissolve until clear; after the material is completely dissolved, cool to -15°C, slowly drop 16.8g (69.3mmol) of iodomethyl pivalate, and control the solution temperature within -10 to -15°C; after the dropwise addition is complete, continue the reaction for 3-4 hours, take samples, and monitor the reaction progress by HPLC. When the cefditoren sodium residue is less than ≤1.0%, stop the reaction; add 250ml ethyl acetate and 150mL purified water to the reaction solution, stir and extract for 30 minutes ; Layer the mixture, add 250 mL of ethyl acetate to the aqueous phase, and stir and extract for 15 minutes; layer the mixture, combine the organic phases, add 150 mL of purified water, and stir and wash for 15 minutes; layer the mixture, remove the aqueous phase, and retain the organic phase; perform vacuum distillation on the organic phase and concentrate it until the fluidity is poor, then stop concentrating, add 250 mL of ethanol for crystallization, cool the crystallized material to 0-5°C, and fully stir and crystallize for 1 hour; filter the mixture, soak the washed material with 200 mL of ethanol, and vacuum dry it at 40°C to obtain 31.0 g (49.9 mol) of cefditoren pivoxil with a purity of 99.2% and a molar yield of 79.2%.
[0048] Example 2: A method for synthesizing cefditoren pivoxil
[0049] Add 30 mL of tetrahydrofuran and 140 mL of purified water to the reaction flask, stir and cool to 0-5°C; add 50 g (154.6 mmol) of 7-ATCA and 68 g (194 mmol) of AE active ester to the reaction flask, wash the flask wall with 15 mL of purified water, continue stirring and cool to 0°C; slowly drop 20.3 g (201.0 mmol) of triethylamine to the reaction solution, and control the solution temperature within 0-5°C. After the dropwise addition is completed, stir and react for 3 hours until the solution becomes clear; take a sample and detect the 7-ATCA residue by HPLC. The reaction is terminated if the residue is less than ≤1.0%.
[0050] Add 500mL of dichloromethane to the reaction flask, stir and wash for 15 minutes; separate the layers, retain the aqueous phase, and add 300mL of dichloromethane, stir and wash for 15 minutes; separate the layers, retain the aqueous phase, and transfer it to another reaction flask, add 500mL of acetone; stir and warm to 25°C; add 7.53g (89.63mmol) of sodium bicarbonate to the reaction flask in portions, stir and crystallize for 2 hours; filter with suction, wash the material with 170mL of acetone, and vacuum dry at 40°C to obtain 45.2g (81.4mmol) of cefditoren sodium;
[0051] Add 250mL dimethylformamide and 35g (63mmol) of cefditoren sodium to the reaction flask, heat to 35°C, and stir to dissolve until clear; after the material is completely dissolved, cool to -15°C, slowly drop 19.8g (81.9mmol) of iodomethyl pivalate, and control the solution temperature within -10 to -15°C; after the dropwise addition is complete, continue the reaction for 3-4 hours, take samples, and monitor the reaction progress by HPLC detection. When the cefditoren sodium residue is less than ≤1.0%, stop the reaction; add 250ml ethyl acetate and 150mL purified water to the reaction solution, stir and wash for 30 minutes ; Layer the mixture, add 250 mL of ethyl acetate to the aqueous phase, and stir and extract for 15 minutes; layer the mixture, combine the organic phases, add 150 mL of purified water, and stir and extract for 15 minutes; layer the mixture, remove the aqueous phase, and retain the organic phase; perform vacuum distillation on the organic phase and concentrate it until the fluidity is poor, then stop concentrating, add 250 mL of ethanol for crystallization, cool the crystallized material to 0-5°C, and fully stir and crystallize for 1 hour; filter the mixture, soak and wash the material with 200 mL of ethanol, and vacuum dry it at 40°C to obtain 30.2 g (48.7 mol) of cefditoren pivoxil with a purity of 99.0% and a molar yield of 77.2%.
[0052] Example 3: A method for synthesizing cefditoren pivoxil
[0053] Add 30 mL of tetrahydrofuran and 140 mL of purified water to the reaction bottle, stir and cool to 0-5°C; add 50 g (154.6 mmol) of 7-ATCA and 68 g (194 mmol) of AE active ester to the reaction bottle, wash the bottle wall with 15 mL of purified water, continue stirring and cool to 0°C; slowly drop 23.5 g (231.9 mmol) of triethylamine to the reaction solution, and control the solution temperature within 0-5°C. After the dropwise addition is completed, stir and react for 3 hours until the solution becomes clear; take a sample and detect the 7-ATCA residue by HPLC. The reaction is terminated if it is less than ≤1.0%.
[0054] Add 550mL of dichloromethane to the reaction bottle, stir and wash for 15 minutes; separate the layers, retain the aqueous phase, and add 350mL of dichloromethane, stir and wash for 15 minutes; separate the layers, retain the aqueous phase, and transfer it to a 1.5L reaction bottle, add 500mL of acetone; stir and warm to 25°C; add 8.18g (97.4mmol) of sodium bicarbonate to the reaction bottle in portions, stir and crystallize for 2 hours; filter with suction, wash the material with 200mL of acetone, and vacuum dry at 40°C to obtain 42.9g (77.2mmol) of cefditoren sodium;
[0055] Add 260mL dimethylformamide and 35g (63mmol) of cefditoren sodium to the reaction flask, heat to 35°C, and stir to dissolve until clear; after the material is completely dissolved, cool to -15°C, slowly drop 22.9g (94.5mmol) of iodomethyl pivalate, and control the solution temperature within -10 to -15°C; after the dropwise addition is complete, continue the reaction for 3-4 hours, take samples, and monitor the reaction progress by HPLC. When the cefditoren sodium residue is less than ≤1.0%, stop the reaction; add 250ml ethyl acetate and 150mL purified water to the reaction solution, stir and wash for 30 minutes ; Layering, add 250mL of ethyl acetate to the aqueous phase, stir and extract for 15 minutes; layering, combine the organic phases, add 150mL of purified water, stir and extract for 15 minutes; layering, remove the aqueous phase, and retain the organic phase; concentrate the organic phase by vacuum distillation until the fluidity is poor, then stop concentrating, add 250mL of ethanol for crystallization, and cool the crystallized material to 0-5°C, fully stir and crystallize for 1 hour; filter, soak and wash the material with 200mL of ethanol, and vacuum dry at 40°C to obtain 30.5g (49.1mol) of cefditoren pivoxil with a purity of 99.1% and a molar yield of 77.9%.
[0056] Comparative Example 1: A method for synthesizing cefditoren pivoxil
[0057] Except for reacting cefditoren acid with sodium isooctanoate to form a salt to obtain cefditoren sodium, the method and steps are the same as those in the embodiment.
[0058] Comparative Example 2: A method for synthesizing cefditoren pivoxil
[0059] Except for reacting cefditoren acid with diisopropylamine to form a salt to obtain cefditoren acid diisopropylamine salt, the method and steps are the same as those in the embodiment.
[0060] Parameter comparison table of product quality obtained in Example 1 and comparative examples 1 and 2
[0061]
[0062] As can be seen from the above table, reacting cefditoren acid with sodium bicarbonate can reduce the contents of Δ-3 isomer, maximum single impurity and total impurity in the final cefditoren pivoxil, and can improve and increase the cefditoren pivoxil content and molar yield, compared with reacting cefditoren acid with sodium isooctanoate or reacting cefditoren acid with diisopropylamine.
[0063] The foregoing description of specific exemplary embodiments of the present invention is for the purpose of illustration and demonstration. These descriptions are not intended to limit the present invention to the precise form disclosed, and it is clear that many changes and variations can be made based on the above teachings. The purpose of selecting and describing the exemplary embodiments is to explain the specific principles of the present invention and its practical application, so that those skilled in the art can realize and utilize various different exemplary embodiments of the present invention and various different selections and changes. The scope of the present invention is intended to be limited by the claims and their equivalents.
Claims
1. A method for synthesizing cefditoren pivoxil, characterized in that: The synthesis method comprises the following steps: (1) Using the cephalexin intermediate 7-ATCA (7-amino-3-[(Z)-2-(4-methyl-5-thiazolyl) vinyl]-3-cephem-4-carboxylic acid) as the starting material, a substitution reaction is carried out with AE active ester (2-methoxyimino-2-(2-amino-4-thiazolyl)-(z)-thioacetic acid benzothiazolyl ester) under the action of a catalyst triethylamine to obtain cefditoren acid. The reaction formula is as follows: (2) subjecting the cefditoren acid obtained in step (1) to a salt-forming reaction with sodium bicarbonate to obtain cefditoren sodium, the reaction formula of which is as follows: (3) subjecting the cefditoren sodium obtained in step (2) to an esterification reaction with iodomethyl pivalate, followed by extraction, washing, distillation concentration, and drying to obtain the product cefditoren pivoxil, wherein the reaction formula is as follows:
2. The synthesis method according to claim 1, characterized in that The specific steps of step (1) include: adding the cephalosporin intermediate 7-ATCA and AE active ester to tetrahydrofuran, adding catalyst triethylamine, and controlling the solution temperature to be within 0-5° C., adding dropwise and stirring the reaction until the solution becomes clear, thereby obtaining cefditoren acid; Wherein, the molar ratio of the 7-ATCA, AE active ester and triethylamine is 1:(1.0-1.5):(1.0-1.5); preferably, the molar ratio of the 7-ATCA, AE active ester and triethylamine is 1:(1.0-1.3):(1.0-1.3); most preferably, the molar ratio of the 7-ATCA, AE active ester and triethylamine is 1:1.1:1.
2.
3. The synthesis method according to claim 2, characterized in that The reaction time is 2-5 hours; and / or, sampling the cefditoren acid obtained in step (1) and detecting the 7-ATCA residue by HPLC. The reaction is terminated when the residue is less than ≤1.0%.
4. The synthesis method according to claim 1, characterized in that The specific steps of step (2) include: reacting the cefditoren acid solution obtained in step (1) with sodium bicarbonate after passing through an organic solvent, and fully stirring and crystallizing; then suction filtering, washing the material with acetone, and vacuum drying to obtain cefditoren sodium; Wherein, the molar ratio of 7-ATCA to sodium bicarbonate is 1:(0.52-0.65); preferably, the molar ratio of 7-ATCA to sodium bicarbonate is 1:(0.54-0.59); most preferably, the molar ratio of 7-ATCA to sodium bicarbonate is 0.54:0.
56.
5. The synthesis method according to claim 4, characterized in that The organic solvent is dichloromethane; the washing method is double washing; the time of each washing is 10-30 minutes; and / or the crystallization time is 1-4 hours; and / or the temperature of the vacuum drying is 30-50°C.
6. The synthesis method according to claim 1, characterized in that The specific steps of step (3) include: adding the cefditoren sodium obtained in step (2) into dimethylformamide, heating to dissolve and then cooling; then slowly adding iodomethyl pivalate dropwise to react, and controlling the solution temperature to be within -10°C to -15°C; then extracting with an organic solvent, washing with water, distilling under reduced pressure, crystallizing, cooling, filtering, washing, and vacuum drying to obtain the product cefditoren pivoxil; Wherein, the molar ratio of cefditoren sodium to iodine methyl pivalate is 1:(1.0-1.5); preferably, the molar ratio of cefditoren sodium to iodine methyl pivalate is 1:(1.0-1.3); most preferably, the molar ratio of cefditoren sodium to iodine methyl pivalate is 1:1.
1.
7. The synthesis method according to claim 6, characterized in that The heating temperature is 25°C-45°C; and / or, the cooling temperature is -15°C; and / or, the reaction time is 3-4h.
8. The synthesis method according to claim 6, characterized in that The organic solvent is ethyl acetate; the extraction method is two extractions, the first extraction time is 25-40 minutes, and the second extraction time is 10-30 minutes; The water washing is performed once, and the washing time is 10-30 minutes.
9. The synthesis method according to claim 1, characterized in that The obtained product cefditoren pivoxil is sampled and the reaction is monitored by HPLC. When the residual cefditoren sodium is less than 1.0%, the reaction is stopped.
10. The synthesis method according to claim 1, characterized in that The crystallization is ethanol crystallization; and / or, the washing is ethanol immersion washing; and / or, the vacuum drying temperature is 40°C.
Citation Information
Patent Citations
Preparation method of cefditoren pivoxil
CN104513256A
Preparation method of cefditore
CN105175432A
Preparation method of cefditoren pivoxil
CN106366097A
Method for synthesizing cefditoren pivoxil
CN109180704A
Preparation method of cefditoren pivoxil intermediate
CN116332955A
